Founded in April 2015, the Atriva Therapeutics GmbH founders team encompasses renowned German virologists and seasoned international business executives. In the past 10 years the founding team has been successfully working together in several anti-viral projects. More recently several team members were instrumental for the success of Activaero GmbH (acquired by Vectura for € 130 Mio in 2014)
An extended founder’s round in late 2015 provided the financial basis for ATRIVA’s start-up and enabled the company to execute the necessary preclinical work on selected lead compounds, namely re-purposed MEK inhibitors for the indication Influenza in high-risk patients.
In 2016 Atriva could attract a group of private Dutch and German investors, led by the Stichting Participatie Atriva, a private foundation constituted according to Dutch laws. Together with Europe’s largest Seed Fund, the German Hightech-Gründerfonds, who joined the round as co-lead investor, and the scientific founders, who substantially contributed to this financing round, an extended seed round in total of € 3 Mio could be closed.
The proceeds of the seed round are dedicated to the preclinical development of Atriva’s lead candidate, the MEK-inhibitor ATR-002 in the indication Influenza in high-risk patients. The key development objectives are an oral treatment regimen of 5 days and start of clinical development of the lead candidate ATR-002 in mid-2018.